The global Compounding Chemotherapy Market is on a steady rise, valued at USD 5.34 billion in 2024 and expected to reach USD 9.97 billion by 2034, growing at a CAGR of 6.44% during the forecast period from 2025 to 2034.
This impressive growth is propelled by the increasing global burden of cancer, advancements in pharmaceutical compounding technology, and a rise in personalized treatment demand—especially among the aging population. The market is further energized by evolving practices in precision medicine and sterile compounding techniques.
2024 Market Value: USD 5.34 billion
2034 Market Forecast: USD 9.97 billion
CAGR (2025–2034): 6.44%
North America Share (2024): ~47%
Asia Pacific Growth Outlook: Fastest CAGR globally
Sterile Compounding Share (2024): ~76%
Below is an overview of the top companies shaping this rapidly growing industry, along with brief insights into their business, product focus, and estimated market footprint.
About: A global healthcare leader based in the U.S., Baxter focuses on critical care, nutrition, renal, and surgical products.
Products: Chemotherapy compounding systems, IV solutions, infusion pumps.
Market Cap: Approx. USD 20 billion.
About: German-based healthcare company specializing in medical devices, pharmaceutical products, and services.
Products: Compounding systems, sterile preparations, infusion solutions.
Market Cap: Privately held; annual revenue exceeds USD 8 billion.
About: A subsidiary of Fresenius SE, focused on lifesaving medicines and technologies.
Products: Oncology drugs, IV drugs, and compounding services.
Market Cap: Parent company approx. USD 20+ billion.
About: A Spanish multinational specializing in plasma-derived medicines and hospital pharmacy services.
Products: Oncology compounding services, IV solutions.
Market Cap: ~USD 10 billion.
About: U.S.-based company focused on infusion therapy and oncology drug delivery.
Products: IV sets, infusion pumps, closed system transfer devices.
Market Cap: ~USD 3.5 billion.
About: Leading provider of outsourced sterile compounding services in the U.S.
Products: Pre-filled chemotherapy admixtures.
Market Cap: Operates under Cencora (formerly AmerisourceBergen), ~USD 50 billion.
About: U.S.-based pharmaceutical manufacturer with a strong focus on compounding automation.
Products: Sterile injectable medications, custom chemotherapy compounds.
Market Cap: Private entity; estimated revenue USD 1 billion+.
About: Specialty pharmacy focused on providing 503B outsourcing services.
Products: Sterile injectable chemotherapy solutions.
Market Cap: Private; significant presence in hospital networks.
About: U.S.-based FDA-registered 503B outsourcing facility.
Products: Ready-to-administer sterile oncology drugs.
Market Cap: Private; small to mid-sized operation.
About: Belgium-based global leader in pharmaceutical compounding.
Products: APIs, compounding bases, and sterile compounding solutions.
Market Cap: ~USD 1.2 billion.
About: U.S.-based compounding pharmacy known for human and veterinary care.
Products: Customized cancer therapy compounds.
Market Cap: Private; moderate revenue scale.
About: Previously Avella; now a division of OptumRx under UnitedHealth.
Products: Personalized oncology medications.
Market Cap: UnitedHealth Group’s overall market cap ~USD 450 billion.
About: Specializes in sterile pharmaceutical compounding for hospitals.
Products: Chemotherapy injectables and admixtures.
Market Cap: Privately held.
About: U.S.-based 503A and 503B compounder with modern production facilities.
Products: Oncology-focused sterile injectables.
Market Cap: Private; large-scale expansion in recent years.
About: Digital pharmacy offering fast delivery and personalized medication.
Products: Personalized compounded chemotherapy support.
Market Cap: Estimated over USD 1 billion in private valuations.
About: Fortune 500 healthcare giant distributing pharmaceuticals and technology.
Products: Oncology supply chain solutions, compounding support services.
Market Cap: ~USD 75 billion.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Compounding chemotherapy involves customizing chemotherapy medications to suit individual patient needs, including dosages, formulations, and delivery methods.
Sterile compounding ensures the preparation is free from microbial contamination, which is critical for immunocompromised cancer patients receiving injectable medications.
North America leads the market, accounting for approximately 47% of total global revenue in 2024.
Trends include personalized medicine, automation in compounding facilities, and strict regulatory oversight for safety and sterility.
Some of the leading companies include Baxter, Fresenius Kabi, ICU Medical, Fagron, and McKesson Corporation, among others.
Source : https://www.towardshealthcare.com/insights/compounding-chemotherapy-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5889
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More
QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse… Read More
Kyoto, Japan July 2025 A groundbreaking collaboration has been formed between Kansai Startup Academia Coalition (KSAC), led by Kyoto University,… Read More